

Schedule of Accreditation



| | |
|---|---|
| Organisation Name | National Virus Reference Laboratory |
| Trading As | |
| INAB Reg No | 326MT |
| Contact Name | Eimear Malone |
| Address | University College Dublin, Belfield, Dublin, D4 |
| Contact Phone No | 01-7161319 |
| Email | eimear.malone@ucd.ie |
| Website | |
| Accreditation Standard | EN ISO 15189 |
| Standard Version | 2012 |
| Date of award of accreditation | 09/09/2014 |
| Scope Classification | Microbiology and virology |
| Services available to the public ¹ | No |

¹ Refer to document on interpreting INAB Scopes of Accreditation

| Sites from which accredited services are delivered | | |
|--|---|---|
| (the detail of the accredited services delivered at each site are on the Scope of Accreditation) | | |
| | Name | Address |
| 1 | NVRL Satellite Laboratory Backweston (NSLB) | Lab 5, Dept. of Agriculture Food and the Marine, Backweston Laboratory Campus, Ballymadeer, Celbridge, Celbridge, Kildare, Ireland, W23X3PH |
| 2 | Head Office | University College Dublin, Belfield, Dublin, D4 |

Scope of Accreditation

Head Office

Microbiology and Virology

Category: A

| Medical pathology field - Test | Test/assay | Specimen Type | Equipment/Technique | Method (CE/Non-CE/In house developed/based on standard method) | Range of measurement | Std. ref & SOP |
|--|-------------------------------------|--|------------------------------|--|--|------------------------------|
| 1015 Detection and/or identification of bacterial, parasite, fungal and viral nucleic acids - .03 Nucleic acid amplification tests, CE marked commercial systems | Altona SARS-CoV-2 RT-PCR | Respiratory swabs | MagNa Pure 96 | CE Marked | Qualitative | LP-CL3-065 |
| | Aptima Mycoplasma Genitalium Assay | Aptima collection device - Anal swab, endocervical swab, urine | Hologic Panther System | CE Marked | Qualitative | VAL/MVIR/225 and LP/MVIR/186 |
| | BioFire Filmarray Respiratory Panel | Respiratory Aspirates, BALS, Respiratory Swabs | Biofire Filmarray Instrument | CE Marked Commercial | Qualitative | LP/MVIR/183 |
| | CMV DNA | Human serum and plasma | Taqman 7500 analyser | CE marked with validated modification | Plasma-Quantitative range 500-1 x 10 ^{*7} Copies/ml | LP/MVIR/085 |
| | CT/NG | Urine and swabs | Panther | CE | Not Detected RLU < 85 Equivocal 85-250 Detected 250-<4500 | LP/MVIR/186 |

| | | | | | |
|--|---|--|---------------------------------------|---|------------------------------|
| Detection of Adenovirus using the Altona RealStar Adenovirus PCR Kit 1.0 | Serum/Plasma | PSH, Magnapure 96, Qiagility, Taqman 7500 FAST | CE Marked Commercial | 10*3 - 10*8 copies/ml | LP/MVIR/200 |
| Detection of viruses in CSF samples using the Altona RealStar HSV, VZV & Entero PCR kits | CSF, Serum, Plasma | EasyMAG ® Automated Extractor, Qiagility | CE Marked | Detected, Not Detected | LP/MVIR/220 |
| EBV DNA | Human serum and plasma Whole Blood | Taqman 7500 analyser | CE marked with validated modification | Plasma-Quantitative range 500 -50 X 10* 7 Copies/ml | LP/MVIR/089 |
| HCV II Genotyping | Human serum and plasma | Abbott real time assay | CE | > 500 IU/ml Required for Genotyping | LP/MVIR/128 |
| HCV RNA | | Abbott real time assay | CE | Quantitative Range 12-10*8 IU/ml | LP/MVIR/125 |
| Hepatitis B Virus | | Abbott real time assay | CE | Quantitative Range 10-10*9 IU/ml | LP/MVIR/135 |
| Immunodeficiency virus type 1 | | Abbott real time assay | CE | Quantitative Range 40-10*7 Copies/ml | LP/MVIR/120 |
| NxTAG Respiratory Pathogen Panel Luminex | Respiratory secretion specimens and respiratory swabs | MagNA pure 96 (Roche), MAGPIX (Luminex) | CE Marked | Detected, Negative | LP/MVIR/198 |
| Parvovirus | Human serum and plasma | Taqman 7500 analyser | CE marked with validated modification | 200-108 IU/ml - Quantitative value reported | LP/MVIR/101 |
| RealStar Altona HHV-6 Assay | Plasma, saliva, swab, CSF | Taqman 7500 Fast | CE Marked | Qualitative | LP/MVIR/112 and VAL/MVIR/233 |
| Real-Time PCR for BK virus DNA (Quantitative) | Serum, Plasma, and Urine samples | Taqman 7500 | CE | Quantitative range 1000- 10*9 Copies/ml | LP/MVIR/177 |
| Real-Time PCR for Hepatitis E Virus | Serum | Taqman 7500 | CE marked with validated modification | Positive HEV RNA results > 1x10(4) IU/ml reported quantitatively. b) Samples with a viral load greater than 1x10(10) IU/ml. this reported as > 10.0 log IU/ml. c)Positive HEV RNA | LP/MVIR/160 |

| | | | | | | | |
|------|--|--|---------------------------------|--|---|---------------|-------------|
| | | | | | results below 1x10(4) IU/ml reported as "DETECTED < 10,000 IU/ml (< 4.0 LogIU/ml)" d) Negative HEV RNA results are reported as "Not detected" | | |
| | Real-time PCR for Herpes Simplex 1 and 2 virus DNA | Swabs, | Taqman 7500 analyser and ViiA 7 | in-house developed | cT < 35 DETECTED cT 35-38 DETECTED at low level cT > 38, repeat | LP/MVIR/107 | |
| | Real-time PCR for JC Virus DNA | CSF, Serum, Urine and Plasma | Taqman 7500 | CE | Blood / CSF - quantitatively as (a) DETECTED < 2.0 Log10 IU/mL (b) If between 90 and 9e10 IU/mL then report number (c) DETECTED > 11.0 Log10 IU/mL | LP/MVIR/152 | |
| | Real-Time RT-PCR for Enterovirus and Parechovirus RNA | Stool, Swab | Taqman 7500 | in-house developed | Detected cT < 38 | 0 LP/MVIR/134 | |
| | RT PCR for the detection and quantification of HIV type 1 (HIV-1) | Plasma | GeneXpert Instrument | CE Marked Commercial | Quantitative Copies /ml | LP/MVIR/173 | |
| | The GeneXpert HCV Viral Load Assay | Plasma | Cepheid GeneXpert IV System | CE Marked | Qualitative range reported as detected <1.08 log IU/ml. Quantitative value reported >1.0 to 8 log IU/ml. | LP-MVIR-173 | |
| | Trichomonas vaginalis on the Panther | Aptima Collection Device | Panther System | CE Marked Commercial | Qualitative | LP/MVIR/097 | |
| 1015 | Detection and/or identification of bacterial, parasite, fungal and viral nucleic acids - .04 Nucleic acid amplification tests, in house developed assays | In-House HIV Genotypic Antiretroviral Resistance Assay | Plasma | Applied Biosystems 3500 Genetic Analyser | In House | N/A | LP/MVIR/176 |

| | | | | | | |
|---|---|---|--|--------------------|---|-------------|
| | Molecular Respiratory Surveillance Real-time PCR Screen | Respiratory secretion specimens and respiratory swabs | ViiA7, Taqman 7500, MagNApure 96 | In house | Qualitative | LP-MVIR-215 |
| | One-Step Real-Time RT-PCR for the Detection of Mumps Virus | Oral Fluid, CSF, other sample types are tested with an NVRL comment | Qiagen, Taqman 7500 FAST | In House | Qualitative | LP/MVIR/112 |
| | Real-Time PCR for Adenovirus DNA | Swabs, Stool | Taqman 7500 analyser and/or ViiA 7 | in-house developed | cT < 35 DETECTED cT 35-38 DETECTED at low level cT > 38, repeat | LP/MVIR/107 |
| | Real-time PCR for the detection of Norovirus, Astrovirus, Sapovirus, Adenovirus type F, Rotavirus and Rotarix (Gastro screen) | Faecal | Roche MagNA Pure 96, ABI 7500/ViiA7 | In House | Detected cT ≤35 | LP/MVIR/153 |
| | Real-Time PCR for Varicella Zoster DNA | Swabs, | Taqman 7500 analyser and ViiA 7 | in-house developed | cT < 35 DETECTED cT 35-38 DETECTED at low level cT > 38, repeat | LP/MVIR/107 |
| 1015 Detection and/or identification of bacterial, parasite, fungal and viral nucleic acids - .05 Nucleotide sequencing & analysis | HBV Genotyping/Resistance | Serum/Plasma | Manual Qiagen, RT-PCR (nested), Sanger sequencing (ABI 3500Dx) | In House | >=log 3 IU/ml | LP/MVIR/193 |
| | HCV Genotyping by Sanger Sequencing | | Manual Qiagen, RT-PCR (nested), Sanger sequencing (ABI 3500Dx) | In House | >=log 4 IU/ml | LP/MVIR/197 |
| 1018 Detection of antibody response to infection using appropriate CE marked commercial techniques - .01 Particle agglutination, using CE marked commercial systems | TP-PA | Human serum and plasma | Manual | CE | Negative Indeterminate Pos 1:80, 1:160, 1:320, 1:640, 1:1280 | LP/VSER/008 |
| 1018 Detection of antibody response to infection using appropriate CE marked commercial techniques - .02 Enzyme immunoassay, using CE | Anti-HBc | | Vidas | CE | Negative ≥1.4 Equivocal ≥1 to <1.4 Positive <1 | LP/VSER/001 |

| | | | | | | |
|---------------------------|---------------------------|-------------|--------|----|--|-------------|
| marked commercial systems | | | | | | |
| | CMV IgM | | Vidas | CE | Negative <0.7 Equivocal ≥0.7 to <0.9 Positive ≥0.9 | LP/VSER/001 |
| | Cytomegalovirus IgM | | Manual | CE | < Cut-off (CO) Negative Lower CO to Upper CO Equivocal ≥Upper CO Positive | LP/VSER/075 |
| | Fortress HEV IgG | | Manual | CE | ≤0.899 Negative 0.9-1.099 Equivocal 1.100-2.999 Weak Positive ≥3.000 Positive | LP/VSER/075 |
| | Fortress HEV-IgM | | Manual | CE | ≤0.899 Negative 0.9-1.099 Equivocal 1.100-2.999 Weak Positive ≥3.000 Positive | LP/VSER/075 |
| | Genscreen Ultra HIV Ag/Ab | | Manual | CE | ≤0.899 Negative 0.900-1.000 Equivocal 1.001-2.999 Weak Positive ≥3.00 Positive | LP/VSER/075 |
| | HAV IgM | | Vidas | CE | Negative <0.4 Equivocal ≥0.4 to <0.499 Positive ≥0.500 | LP/VSER/001 |
| | Herpes Select 1 | Human serum | Manual | CE | <0.9 Negative ≥0.900-≤1.100 Equivocal N/A Weak Positive ≥1.1 Positive | LP/VSER/075 |
| | Herpes Select 2 | | Manual | CE | <0.9 Negative ≥0.900-≤1.100 Equivocal | LP/VSER/075 |

| | | | | | |
|--|------------------------|---|-------------------------|--|--|
| | | | | N/A Weak Positive ≥1.1 Positive | |
| HIV 1 P24 Antigen component of VIDAS assay | Serum and Plasma | Biomerieux VIDAS | CE Marked | <3.0 pg/ml of p24 Ag – Negative ≥ 3.0 and < 5.0 pg/ml of p24 Ag - Equivocal ≥ 5.0 pg/ml of p24 Ag- Positive | LP-VSER-053 |
| HIV screening | Human serum and plasma | Vidas | CE | Negative Ab <0.25 Negative Ag<0.25 Positive Ab ≥0.25 Positive Ag ≥0.25 | LP/VSER/001 |
| Innotest HCV | Serum/Plasma | ELISA | CE Marked Commercial | Neg (-/=0.800, - /=3.000) | LP/VSER/075 |
| Leptospira IgM | Human serum | Manual | CE | ≤0.899 Negative 0.900-1.100 Equivocal 1.101-1.999 Weak Positive ≥2.000 Positive | LP/VSER/075 |
| Liaison Treponema Screen Assay | Serum and plasma | Diasorin Liaison XL | CE Marked | Qualitative | VAL/VSER/166 and LP/VSER/077 |
| Liaison XL Anti-HBc assay | Serum/Plasma | Chemiluminescence immunoassay (CLIA) technology for the qualitative determination of total antibodies to hepatitis B core antigen (anti-HBc) in human serum or plasma samples | CE | Samples with anti-HBc levels between an index value of >/=0.300-0.900 are graded weak positive. Samples with an index value of 0.300 are graded positive | The manufacturer's direction circular and the NVRL procedure LP/VSER/077 Operation and Maintenance of the Diasorin Liaison XL |
| Liaison XL Murex Anti-HDV Assay | Serum and plasma | Diasorin Liaison XL | CE Marked | Qualitative | VAL/VSER/162 and LP/VSER/077 |
| Measles IgM | Human serum and plasma | Manual | CE | Serum ≤0.899 Negative 0.900-1.099 Equivocal 1.100-1.999 Weak Positive ≥2.000 Positive | LP/VSER/075 |

| | | | | | |
|--------------------------|------------------------|---------------------|----|---|-------------|
| Monolisa HCV Ab | Human serum and plasma | Manual | CE | ≤0.899 Negative 0.900-1.000 Equivocal 1.001-2.999 Weak Positive ≥3.00 Positive | LP/VSER/075 |
| Mumps IgG | | Diasorin Liaison XL | CE | Negative ≤9 Equivocal ≥9.0 to ≤10.99 Weak positive ≥11.0 to ≤49.99 Positive ≥50 | LP/VSER/077 |
| Mumps IgM | Human serum and plasma | Manual | CE | Serum <0.856 Negative ≥ 0.856 - <1.000 Equivocal ≥ 1.000 - <2.000 Weak Positive ≥2.000 Positive | LP/VSER/075 |
| Murex HBsAg | Human serum and plasma | Manual | CE | ≤0.899 Negative 0.9 – 1.000 Equivocal 1.001-2.999 Weak Positive ≥3.000 Positive | LP/VSER/075 |
| Murex HBsAg Confirmatory | | Manual | CE | Positive/Negative | LP/VSER/075 |
| Murex HTLV I/II | | Manual | CE | ≤0.899 Negative 0.900-1.000 Equivocal 1.001-2.999 Weak Positive ≥3.00 Positive | LP/VSER/075 |
| Ortho HCV | | Manual | CE | ≤0.899 Negative 0.900-1.000 Equivocal 1.001-2.999 Weak Positive ≥3.00 Positive | LP/VSER/075 |
| Syphilis IgM | | Manual | CE | ≤0.899 Negative 0.9-1.000 Equivocal | LP/VSER/075 |
| | | | | | |

| | | | | | | |
|---|---------------------------------|------------------------|------------------------|-----------|--|-------------|
| | | | | | 1.001-1.999 Weak Positive ≥2.000 Positive | |
| | Toxo IgG II | | Vidas | CE | Negative <4 Equivocal ≥4 to <8 Positive ≥8 | LP/VSER/001 |
| | Toxo IgM | | Vidas | CE | Negative <0.55 Equivocal ≥0.55 to <0.65 Positive ≥6.5 | LP/VSER/001 |
| | VIDAS CMV IgG Assay | Serum | BioMerieux VIDAS | CE Marked | Quantitative | LP/VSER/001 |
| | Vidas HIV 1 P24 11 Confirmatory | Human serum and plasma | Vidas | CE | Neutralisation % ≥60% p24 antigen confirmed ≤60% negative | LP/VSER/001 |
| 1018 Detection of antibody response to infection using appropriate CE marked commercial techniques - .04 Line immunoassay, using CE marked commercial systems | INNO-LIA HCV Score | | AUTO-LIA | CE | Negative Indeterminate Positive | LP/VSER/016 |
| | INNO-LIA HIV I/II | | Immunoblot | CE | Negative Indeterminate Positive | LP/VSER/016 |
| | INNO-LIA HTLV I/II Score | | AUTO-LIA | CE | Negative Indeterminate Positive | LP/VSER/016 |
| | The INNO-LIA Syphilis Score | Serum | Auto Lia 48 Instrument | CE Marked | Positive, Negative, Indeterminate | LP-VSER-016 |
| 1018 Detection of antibody response to infection using appropriate CE marked commercial techniques - .07 Chemiluminescent microparticle immunoassay, using CE | Anti-HBc IgM | Human serum and plasma | Architect i4000 | CE | S/CO ≤ 0.999 Negative S/CO 1.000 – 2.999 Weak Positive S/CO ≥ 3.000 Positive | LP/VSER/050 |

| | | | | | |
|---------------------------|--------------|---------------------|----|---|-------------|
| marked commercial systems | | | | | |
| | Anti-HBc II | Architect i4000 | CE | S/CO ≤ 0.899 Negative S/CO 0.900 - 1.000 Equivocal S/CO 1.001 - 1.999 Weak Positive S/CO ≥ 2.000 Positive | LP/VSER/050 |
| | Anti-HBe | Architect i4000 | CE | S/CO ≥ 1.101 Negative S/CO 1.002 - 1.100 Equivocal S/CO 0.800 - 1.001 Weak Positive S/CO ≤ 0.800 Positive | LP/VSER/050 |
| | Anti-HBs | Architect i4000 | CE | 0.0 - 0.49 mIU/ml No antibodies detected 0.50 – 9.99 mIU/ml Less than 10 mIU/ml ≥ 10 mIU/mL mIU/ml value reported | LP/VSER/050 |
| | | Diasorin Liaison XL | CE | ≤10 IU/ml 10.1-99.9 mIU/ml ≥100 IU/ml | LP/VSER/077 |
| | Anti-HCV | Architect i4000 | CE | S/CO ≤ 0.799 Negative S/CO 0.800 - 1.000 Equivocal S/CO 1.001 - 4.999 Weak Positive S/CO ≥ 5.000 Positive | LP/VSER/050 |
| | Borrelia IgG | Diasorin Liaison XL | CE | Negative ≤9.99 Equivocal ≥10.0 to ≤14.99 Weak positive ≥15.0 to ≤29.99 Positive ≥30 | LP/VSER/077 |

| | | | | |
|-------------|---------------------|----|--|-------------|
| CMV IgG | Architect i4000 | CE | ≤ 5.999 AU/mL Negative 6.000 – 14.999 AU/mL Weak Positive ≥ 15.000 AU/mL Positive | LP/VSER/050 |
| CMV IgM | Architect i4000 | CE | Index ≤ 0.849 Negative Index 0.850 – 0.999 Equivocal Index 1.000 – 1.999 Weak Positive Index ≥2.000 Positive | LP/VSER/050 |
| EBNA IgG | Diasorin Liaison XL | CE | Negative ≤4.99 Equivocal ≥5.00 to ≤20.00 Weak positive ≥20.01 to ≤30.00 Positive ≥30.01 | LP/VSER/077 |
| EBV IgM | Diasorin Liaison XL | CE | Negative ≤19.9 Equivocal ≥20.0 to ≤39.9 Weak Positive ≥40.0 to ≤79.9 Positive ≥80 | LP/VSER/077 |
| EBV VCA IgG | Diasorin Liaison XL | CE | Negative ≤19.9 Equivocal ≥20.0 to ≤29.9 Weak positive ≥30.0 to ≤39.9 Positive ≥40 | LP/VSER/077 |
| HAVAb-IgG | Architect i4000 | CE | S/CO ≤ 0.899 Negative S/CO 0.900 - 1.000 Equivocal S/CO 1.001 - 1.999 Weak Positive S/CO ≥ 2.000 Positive | LP/VSER/050 |

| | | | | | | |
|--|-----------------|-------------|---------------------|----|--|-------------|
| | HAVAb-IgM | | Architect i4000 | CE | S/CO ≤ 0.799 Negative S/CO 0.800 - 1.199 Equivocal S/CO 1.200 – 2.999 Weak Positive S/CO ≥ 3.000 Positive | LP/VSER/050 |
| | HBeAg | | Architect i4000 | CE | S/CO ≤ 0.899 Negative S/CO 0.900 - 1.000 Equivocal S/CO 1.001 - 1.100 Weak Positive S/CO ≥1.101 Positive | LP/VSER/050 |
| | HBsAg | | Architect i4000 | CE | S/CO ≤ 0.799 Negative S/CO 0.800 - 1.000 Equivocal S/CO 1.001 - 14.999 Weak Positive S/CO ≥ 15.000 Positive | LP/VSER/050 |
| | HCV Ag | | Architect i4000 | CE | 0.000 – 2.999 fmol/L Negative 3.000 – 9.999 fmol/L Weak Positive ≥ 10.000 fmol/L Positive | LP/VSER/050 |
| | HIV Ag/Ab Combo | | Architect i4000 | CE | S/CO ≤ 0.799 Negative S/CO 0.800 - 1.000 Equivocal S/CO 1.001 – 14.999 Weak Positive S/CO ≥15.000 Positive | LP/VSER/050 |
| | HSV 1 / 2 IgG | Human serum | Diasorin Liaison XL | CE | Negative ≤0.89 Equivocal ≥0.9 to ≤1.09 Weak positive ≥1.10 to ≤1.49 | LP/VSER/077 |

| | | | | | |
|---|------------------------|--|----|---|---|
| | | | | Positive ≥ 1.5 | |
| Liaison XL Murex recHTLV-I/II assay | Serum/Plasma | Chemiluminescence immunoassay (CLIA) technology for the qualitative determination of specific antibodies to Human T-cell Lymphotropic Virus (HTLV) Type I and Type II (anti-HTLV I and anti-HTLV II) in human serum and plasma samples | CE | Specimens with signal-to-cut-off (S/CO) ratios < 1.00 are considered non-reactive for HTLV I/II antibodies. Specimens with signal-to-cut-off (S/CO) ratios of ≥ 1.00 - 2.99 are weak positive and ≥ 3.00 are considered positive for HTLV I/II antibodies | The manufacturer's direction circular and the NVRL procedure LP/VSER/077 Operation and Maintenance of the Diasorin Liaison XL |
| Measles IgG | Human serum and plasma | Diasorin Liaison XL | CE | Negative < 13.5 Equivocal ≥ 13.5 to ≤ 16.49 Weak Positive ≥ 16.5 to ≤ 49.99 Positive ≥ 50 | LP/VSER/077 |
| Parvovirus B19 IgG | | Diasorin Liaison XL | CE | Negative < 0.9 Equivocal ≥ 0.9 to < 1.1 Weak positive ≥ 1.1 to < 1.5 Positive ≥ 1.5 | LP/VSER/077 |
| Parvovirus B19 IgM | | Diasorin Liaison XL | CE | Negative < 0.9 Equivocal ≥ 0.9 to < 1.1 Weak positive ≥ 1.1 to < 1.5 Positive ≥ 1.5 | LP/VSER/077 |
| Platelia Mycoplasma pneumonia IgM ELISA | Serum | Detection of anti-mycoplasma pneumonia IgM in human serum by enzyme immunoassay. | CE | OD/CO ≤ 0.899 Negative OD/CO ≥ 0.900 to ≤ 1.000 equivocal, OD/CO ≥ 1.001 to ≤ 1.999 Wk Positive OD/CO ≥ 2.000 positive | The manufacturer's direction circular and the NVRL procedure LP/VSER/075 Enzyme linked immunoassay (ELISA) procedure |
| rHTLV-I/II | Human serum and plasma | Architect i4000 | CE | S/CO ≤ 0.799 Negative | LP/VSER/050 |

| | | | | | | |
|-------------|--|---------------------|----|--|---|-------------|
| | | | | | S/CO 0.800 - 1.000 Equivocal S/CO 1.001 - 1.999 Weak Positive S/CO ≥ 2.000 Positive | |
| Rubella IgG | | Architect i4000 | CE | | ≤ 4.999 IU/ml No antibodies detected 5.000 – 14.999 IU/ml As per algorithm ≥ 15.000 IU/mL Greater than 15 IU/ml | LP/VSER/050 |
| | | Diasorin Liaison XL | CE | | Less than 5 IU/ml <5 IU/ml Detected at low level ≥5.1 to ≤9.999 IU/ml Greater than 10IU/ml ≥10 IU/ml | LP/VSER/077 |
| Rubella IgM | | Architect i4000 | CE | | S/CO ≤ 0.749 Negative S/CO 0.750 – 1.000 Equivocal S/CO 1.001 – 1.999 Weak Positive S/CO ≥ 2.000 Positive | LP/VSER/050 |
| Syphilis TP | | Architect i4000 | CE | | S/CO ≤ 0.499 Negative S/CO 0.500 - 1.000 Equivocal S/CO 1.001 - 3.999 Weak Positive S/CO ≥ 4.000 Positive | LP/VSER/050 |
| Toxo IgM | | Architect i4000 | CE | | S/CO ≤ 0.829 Negative S/CO 0.830 – 0.999 Equivocal S/CO 1.000 – 1.499 Weak Positive S/CO ≥ 1.500 Positive | LP/VSER/050 |

| | | | | | | |
|--|---------|--|---------------------|----|---|-------------|
| | ToxoIgG | | Architect i4000 | CE | ≤ 1.599 IU/ml Negative $1.600 - 2.999$ IU/mL Equivocal ≥ 3.000 IU/mL Positive | LP/VSER/050 |
| | VZV IgG | | Diasorin Liaison XL | CE | Negative ≥ 100 mIU/ml ≤ 100 mIU/ml | LP/VSER/077 |

NVRL Satellite Laboratory Backweston (NSLB)

Microbiology and Virology

Category: A

| Medical pathology field - Test | Test/assay | Specimen Type | Equipment/Technique | Method (CE/Non-CE/In house developed/based on standard method) | Range of measurement | Std. ref & SOP |
|--|-----------------------------------|------------------|-------------------------------|--|------------------------------------|---------------------------|
| 1015 Detection and/or identification of bacterial, parasite, fungal and viral nucleic acids - .03 Nucleic acid amplification tests, CE marked commercial systems | cobas® SARS-CoV-2 & Influenza A/B | Respiratory Swab | cobas® 6800 | CE Marked | | LP/NSLB/014 |
| | Real-time PCR for SARS-CoV-2 | | Roche Cobas 6800 system | CE marked Commercial | Detected, Not Detected, Inhibitory | LP/MVIR/226 |
| | Real-Time RT PCR for SARS-CoV-2 | | ThermoFisher Amplitude System | CE Marked Commercial | Detected, Not Detected, Inhibitory | LP/NSLB/004 & LP/NSLB/009 |